{"id":62332,"date":"2025-12-10T07:06:32","date_gmt":"2025-12-10T06:06:32","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\/"},"modified":"2025-12-10T07:06:32","modified_gmt":"2025-12-10T06:06:32","slug":"polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\/","title":{"rendered":"Polpharma Biologics and Libbs Farmac\u00eautica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases"},"content":{"rendered":"
\n

ZUG, Switzerland–(BUSINESS WIRE)–Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmac\u00eautica! Through this strategic partnership, Libbs Farmac\u00eautica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases in the rapidly growing Brazilian market.<\/b>\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nPolpharma Biologics retains full responsibility for the development and manufacturing of the biosimilar. Libbs Farmac\u00eautica will hold an exclusive license for the commercialization, marketing and distribution of the biosimilar in Brazil. This collaboration opens up exciting new opportunities and demonstrates the shared commitment of both companies to delivering innovative and accessible therapies to patients.\n<\/p>\n

\n\u201cEntering the Brazilian market with a biosimilar is a significant step for Polpharma Biologics and reflects our ongoing mission to expand access to high-quality, affordable biological treatments worldwide,\u201d said Anjan Selz, CEO of Polpharma Biologics. <\/b>\u201cOur collaboration with Libbs Farmac\u00eautica, a company with deep knowledge of the Brazilian market, provides us with strong commercial expertise. Combined with our development and manufacturing capabilities, this partnership will significantly increase access to biological therapies for people in Brazil who are living with autoimmune diseases.\u201d<\/a>\n<\/p>\n

\n“We currently treat more than 15 million patients with our products. This partnership with Polpharma Biologics is fully aligned with Libbs’ strategy of investing in a diversified portfolio of medicines with potential to further expand the Brazilian population’s access to healthcare,” says Alceb\u00edades de Mendon\u00e7a Athayde Junior, CEO of Libbs<\/b>.\n<\/p>\n

\nThis modern therapy offers an effective and well-tolerated option for patients living with autoimmune conditions. The biosimilar medicine is still under development and is expected to be submitted to Anvisa for approval within three years.\n<\/p>\n

\nAbout Polpharma Biologics<\/b>\n<\/p>\n

\nPolpharma Biologics is a biopharmaceutical company focused on the development and manufacturing of biopharmaceuticals and biosimilars for global markets. Our Swiss-based biosimilars-focused entity manages the entire value chain: from product selection and investment allocation to program execution to asset monetization. This ensures rapid progress from concept to launch in close collaboration with our global partners.\n<\/p>\n

\nPolpharma Biologics\u2019 biosimilar portfolio includes a range of high-value programs spanning early development to commercial stages. Our international team of senior experts has extensive experience in program leadership, regulatory strategy, CMC integration, device development, clinical oversight, and quality assurance. By working with trusted CDMOs, we provide end-to-end biosimilars, from cell line development to finished products, across a variety of major therapeutic areas. Our commercial partners help ensure that patients worldwide gain access to these medicines.\n<\/p>\n

\nOur mission is to accelerate access to biologics. To achieve this, we maintain a robust and expanding pipeline of biosimilars in development. More information: https:\/\/polpharmabiologics.com\/<\/a>\n<\/p>\n

\nAbout Libbs<\/b>\n<\/p>\n

\nLibbs is a 100% Brazilian pharmaceutical company with the purpose of transforming knowledge into health. To offer high-quality products and solutions, we work collaboratively in a process of continuous improvement and invest in research and innovation. With 67 years of history and 4,000 employees, we have been, for the eighth consecutive year, among the best companies to work for in Brazil, according to GPTW (Great Place to Work). Our specialties include cardiology, dermatology, gastroenterology, gynecology, hematology, oncology, central nervous system, and respiratory system.\n<\/p>\n

\nIn 2024, we brought healthcare to more than 15 million people through a portfolio comprising 97 product brands in over 200 presentations, across reference, similar, chemotherapeutic, and biosimilar (monoclonal antibodies) categories. Our Biotec is the first industrial-scale monoclonal antibody plant in Brazil, and, in 2024, it gained a Pilot Plant dedicated to the development of biomolecules, scaling up bioprocesses, and producing clinical material for studies through partnerships or as a CDMO.\n<\/p>\n

\nWe invest approximately 10% of our revenue in R&D and maintain initiatives such as the Research Incentive Program (PIP), which supports independent clinical studies. We support causes and campaigns that guide the population regarding prevention, early diagnosis, and treatment. We are always open to developing new partnership projects. More information can be found at www.libbs.com.br<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nRupert Birkett-Eyles
\n
Rupert.birketteyles@ruderfinn.com<\/a>
+44(0) 7876163218\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ZUG, Switzerland–(BUSINESS WIRE)–Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmac\u00eautica! Through this strategic partnership, Libbs Farmac\u00eautica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases in the rapidly growing … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62332","6":"format-standard","7":"category-industry"},"yoast_head":"\nPolpharma Biologics and Libbs Farmac\u00eautica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Polpharma Biologics and Libbs Farmac\u00eautica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ZUG, Switzerland–(BUSINESS WIRE)–Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmac\u00eautica! Through this strategic partnership, Libbs Farmac\u00eautica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases in the rapidly growing ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-10T06:06:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251209073657\/en\/2665341\/22\/Logotype-Polpharma_Biologics.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Polpharma Biologics and Libbs Farmac\u00eautica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases\",\"datePublished\":\"2025-12-10T06:06:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\\\/\"},\"wordCount\":674,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251209073657\\\/en\\\/2665341\\\/22\\\/Logotype-Polpharma_Biologics.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\\\/\",\"name\":\"Polpharma Biologics and Libbs Farmac\u00eautica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251209073657\\\/en\\\/2665341\\\/22\\\/Logotype-Polpharma_Biologics.jpg\",\"datePublished\":\"2025-12-10T06:06:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251209073657\\\/en\\\/2665341\\\/22\\\/Logotype-Polpharma_Biologics.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251209073657\\\/en\\\/2665341\\\/22\\\/Logotype-Polpharma_Biologics.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Polpharma Biologics and Libbs Farmac\u00eautica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Polpharma Biologics and Libbs Farmac\u00eautica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\/","og_locale":"en_US","og_type":"article","og_title":"Polpharma Biologics and Libbs Farmac\u00eautica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases - Pharma Trend","og_description":"ZUG, Switzerland–(BUSINESS WIRE)–Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmac\u00eautica! Through this strategic partnership, Libbs Farmac\u00eautica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases in the rapidly growing ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\/","og_site_name":"Pharma Trend","article_published_time":"2025-12-10T06:06:32+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251209073657\/en\/2665341\/22\/Logotype-Polpharma_Biologics.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Polpharma Biologics and Libbs Farmac\u00eautica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases","datePublished":"2025-12-10T06:06:32+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\/"},"wordCount":674,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251209073657\/en\/2665341\/22\/Logotype-Polpharma_Biologics.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\/","url":"https:\/\/pharma-trend.com\/en\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\/","name":"Polpharma Biologics and Libbs Farmac\u00eautica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251209073657\/en\/2665341\/22\/Logotype-Polpharma_Biologics.jpg","datePublished":"2025-12-10T06:06:32+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251209073657\/en\/2665341\/22\/Logotype-Polpharma_Biologics.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251209073657\/en\/2665341\/22\/Logotype-Polpharma_Biologics.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/polpharma-biologics-and-libbs-farmaceutica-sign-licensing-agreement-for-a-biosimilar-for-autoimmune-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Polpharma Biologics and Libbs Farmac\u00eautica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62332","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62332"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62332\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62332"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62332"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62332"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}